Featured
Striving for early predictors of immunotherapy response to prevent immune-related adverse events in gastrointestinal cancer: An interview with Dr. Dmitrii Shek
“We do patient-centered research. Old school technologies can explore and elucidate the expression of a single marker or a couple of genes, but for cancer, that’s probably not enough. We need to do something more. We need to explore new dimensions. We need to do multiomics in order to fully understand what's going on with the particular patient.
Olivia Habern
All Products
All Areas of Interest